A Phase 3 interventional study of Navtemadlin and Navtemadlin placebo in Myelofibrosis, Post-PV MF and Post-ET Myelofibrosis, sponsored by Kartos Therapeutics, Inc.. Recruiting at 215 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.
Sponsored by Kartos Therapeutics, Inc. (part of Ipsen) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 453 studies in Primary Myelofibrosis with a site in United States — 69 open to participants now, 104 under way, 12 of them phase 3. Primary Myelofibrosis · United States.
Among the 453 studies in Primary Myelofibrosis with a site in United States, this one is the 3rd largest by planned enrollment of the 387 interventional ones that give a count, is one of 16 that started in 2024, is one of 42 in phase 3, reaches primary completion later than 28 of the 103 other live ones, and was the 422nd registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →69 of the 453 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
Damora Therapeutics · Sites in United States, Australia
Ages 18+
University of Utah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
453 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 166 · Phase 2 219 · Phase 3 45
First in 1992; this study’s year is marked. 16 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 40 across the 387 interventional studies, 153 across the 35 observational. Of the 328 that completed or were terminated, 152 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
133 of 453 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kartos Therapeutics, Inc., one of the names counted as Ipsen. Under that name alone:
Kartos Therapeutics, Inc. is the lead sponsor of 16 studies on the registry; 7 are open to participants now.
Ipsen has 5 studies filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
40 of the studies in Primary Myelofibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06479135Phase 3Kartos Therapeutics, Inc.Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | 2026-12-31 |
| NCT06468033Phase 3PharmaEssentiaP1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | 2027-11-18 |
| NCT02934477Center for International Blood and Marrow Transplant ResearchProspective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis | 2026-11 |
| NCT01973881University of Michigan Rogel Cancer CenterQuantitative MRI for Myelofibrosis | 2026-12 |
| NCT06414681University of Kansas Medical CenterCombination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined | 2026-12 |
Add all 40 to your calendar (.ics) → With an account.
Among the 453 studies in Primary Myelofibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.
Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxolitinib. Randomized means that subjects will be assigned to a group by chance, like a flip of a coin. The study is blinded, meaning the subjects, doctors, central endpoint assessors and sponsor will not know which add on treatment (navtemadlin or navtemadlin placebo) the subject is receiving.
Inclusion Criteria for Ruxolitinib Alone Period:
Exclusion Criteria for Ruxolitinib Alone Period:
Inclusion Criteria for Randomized Period:
Exclusion Criteria for Randomized Period:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Navtemadlin administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.
Drug: Navtemadlin · Drug: Ruxolitinib
Navtemadlin placebo administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.
Drug: Navtemadlin placebo · Drug: Ruxolitinib
Navtemadlin is an investigational MDM2 inhibitor
Also known as: KRT-232
Navtemadlin placebo
Also known as: KRT-232
Ruxolitinib is a janus kinase 1/2 inhibitor
Also known as: Jakafi, Jakavi
To compare spleen volume reduction (SVR35) between Arm 1 and Arm 2
The proportion of subjects in each arm with SVR35 by MRI/CT scan (central review) 24 weeks after start of the randomized period
Time frame: 24 weeks
To compare total symptom score reduction (TSS50) between Arm 1 and Arm 2
The proportion of subjects in each arm with a TSS50 by the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 24 weeks after start of the randomized period
Time frame: 24 weeks
To compare time to progression between Arm 1 and Arm 2
Time to progression or death from any cause in subjects randomized to each arm
Time frame: Up to 8 years
To compare overall survival (OS) between Arm 1 and Arm 2
Time to death from any cause in subjects randomized to each arm
Time frame: Up to 8 years
Showing the first 100 of 215 sites across 19 countries. Choose a country and city above to see the rest.
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
Of 22 phase 3 interventional studies under Primary Myelofibrosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 68. This study's planned 30 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Navtemadlin